APOA1 and diabetes mellitus: Since the two classes of diabetes drugs both lower blood glucose but through completely different mechanisms, it is plausible that establishing glycaemic control is a strongly contributing factor to the reduced CVD risk, which may involve a reduction in AGEs ([25] and refs therein), potentially including the ApoA-I protein [20, 26, 27].